NASDAQ
Corcept Therapeutics Incorporated (CORT)
♥ 364 Thanks from members
Corcept Therapeutics (CORT) exhibits strong commercial momentum driven by the robust launch of LIFYORLI and revenue growth from Korlym, though a rich valuation and high SG&A limit near-term upside.